Association between cigarette smoking and Parkinson's disease: A meta-analysis

Archives of Gerontology and Geriatrics

Volumn 61, Issue 3, 2015, Pages 510-516

  Li, Xiao ^a,b   Li, Weihua ^a   Liu, Guixia ^a   Shen, Xu ^b   Tang, Yun ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cigarette smoking; Meta analysis; Pack year; Parkinson's disease

Indexed keywords

ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; GENDER; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; POPULATION RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; RISK FACTOR; SMOKING; ADULT; ADVERSE EFFECTS; FEMALE; HOSPITAL; MALE; META ANALYSIS; MIDDLE AGED;

NICOTINE;

ADULT; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; NICOTINE; PARKINSON DISEASE; RISK FACTORS; SMOKING;

EID: 84943457301     PISSN: 01674943     EISSN: 18726976     Source Type: Journal    
DOI: 10.1016/j.archger.2015.08.004     Document Type: Article

References (29)

1. Allam M.F., Campbell M.J., Castillo A.S.D., Navajas R.F. Parkinson's disease protects against smoking?. Behavioural Neurology 2004, 15:65-71.
2. Allam M.F., Campbell M.J., Hofman A., Del Castillo A.S., Navajas R.F. Smoking and Parkinson's disease: systematic review of prospective studies. Movement Disoroder 2004, 19:614-621.
3. Berlin I., Hunneyball I.M., Greiling D., Jones S.P., Fuder H., Stahl H.-D. A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Psychopharmacology (Berl) 2012, 223:89-98.
4. Carradori S., D'Ascenzio M., Chimenti P., Secci D., Bolasco A. Selective MAO-B inhibitors: a lesson from natural products. Molecular Diversity 2014, 18:219-243.
5. Castagnoli K., Murugesan T.T. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?. Neurotoxicology 2004, 25:279-291.
6. Davie C.A. A review of Parkinson's disease. British Medical Bulletin 2008, 86:109-127.
7. De Lau L., Breteler M.M. Epidemiology of Parkinson's disease. The Lancet. Neurolology 2006, 5:525-535.
8. Derkinderen P., Shannon K.M., Brundin P. Gut feelings about smoking and coffee in Parkinson's disease. Movement Disorder 2014, 29:976-979.
9. Hernán M.A., Takkouche B., Caamaño-Isorna F., Gestal-Otero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Annals of Neurology 2002, 52:276-284.
10. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 27:557-560.
11. Hong D.P., Fink A.L., Uversky V.N. Smoking and Parkinson's disease: does nicotine affect α-synuclein fibrillation?. Biochimica et Biophysica Acta 2009, 1794:282-290.
12. Huxley R.R., Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011, 378:1297-1305.
13. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
14. Li F.J., Ji H.F., Shen L. A meta-analysis of tea drinking and risk of Parkinson's disease. Scientific World Journal 2012, 2012:923464.
15. Maele-Fabry G.V., Hoet P., Vilain F., Lison D. Occupational exposure to pesticides and Parkinson's disease: a systematic review and meta-analysis of cohort studies. Environment International 2012, 46:30-43.
16. Mudo G., Belluardo N., Fuxe K. Nicotinic receptor agonists as neuroprotective neurotrophic drugs: progress in molecular mechanisms. Journal of Neural Transmission 2007, 114:135-147.
17. Noyce A.J., Bestwick J.P., Silveira-Moriyama L., et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology 2012, 72:893-901.
18. Quik M.S. Smoking, nicotine and Parkinson's disease. Trends in Neurosciences 2004, 27:561-568.
19. Quik M., Huang L.Z., Parameswaran N., Bordia T., Campos C., Perez X.A. Multiple roles for nicotine in Parkinson's disease. Biochemical Pharmacology 2009, 78:677-685.
20. Ritz B., Ascherio A., Checkoway H., et al. Pooled analysis of tobacco use and risk of Parkinson disease. Archieves of Neurology 2007, 64:990-997.
21. Rodgman A., Perfetti T.A. The chemical components of tobacco and tobacco smoke 2013, CRC Press Taylor & Francis Group, Boca Raton, Florida, USA. 2nd ed.
22. Schapira A.H.V. Neurobiology and treatment of Parkinson's disease. Trends in Pharmacological Sciences 2009, 30:41-47.
23. Schapira A.H.V. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 2011, 25:1061-1071.
24. Shen L., Ji H.F. Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis. BMJ Open 2013, 3:e003620.
25. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA 2000, 283:2008-2012.
26. Tanner C.M., Goldman S.M., Aston D.A., et al. Smoking and Parkinson's disease in twins. Neurology 2002, 58:581-588.
27. WHO Report on the Global Tobacco Epidemic, 2008: the MPOWER package 2008, WHO, Geneva, Switzerland.
28. Wirdefeldt K., Adami H.-O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. European Journal of Epidemiology 2011, 26:S1-S58.
29. Zhang J., Yu K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998, 280:1690-1691.